FTC Affiliate Disclosure: This article may contain affiliate links. If you enroll through these links, a commission may be earned at no additional cost to you. MEDVi QUAD is a compounded prescription medication that requires evaluation by a licensed clinician. Prescription approval is not guaranteed. This article is not medical advice.
If you found this article because you were reading about MEDVi's GLP-1 weight loss controversy and noticed the company also offers an ED product, you are not alone. The viral New York Times profile, the FDA warning letter, and the surrounding media coverage have made MEDVi one of the most searched telehealth brands in America right now. A portion of that traffic — the portion you are part of — is men who want to know whether the QUAD program is affected by the same issues making headlines.
The short answer is that the FDA warning letter and the GLP-1 regulatory crackdown are about a different product line. The longer answer is that you should still ask hard questions before enrolling in any compounded prescription program, and this article covers the ones that matter.
What the FDA Warning Letter Does and Does Not Cover
The February 2026 FDA warning letter to MEDVi (Letter #721455) specifically addressed the company's GLP-1 weight loss product marketing. The FDA cited concerns that website language falsely suggested MEDVi was the compounder of semaglutide and tirzepatide products and that certain claims implied FDA approval of compounded preparations.
The warning letter did not reference MEDVi's QUAD ED product line. The March 2026 wave of 30-plus FDA warning letters to telehealth companies was also focused exclusively on compounded GLP-1 marketing. The compounded ED category has not been the subject of comparable FDA enforcement activity.
That said, QUAD is still a compounded medication dispensed through a telehealth platform, and the broader regulatory environment for compounded telehealth products is tightening across all categories. The fact that QUAD has not been specifically targeted does not exempt it from the same compounding regulations that apply to every compounded prescription product. It means the current enforcement focus is elsewhere — not that no rules apply.
What QUAD Actually Is
QUAD is a compounded prescription combining four active pharmaceutical ingredients into a single sublingual liquid. You place it under your tongue, hold it for 30 to 60 seconds, and it absorbs directly into your bloodstream without passing through your digestive system.
According to MEDVi's published disclosures, the four ingredients are sildenafil (the active ingredient in Viagra), tadalafil (the active ingredient in Cialis), vardenafil (the active ingredient in Levitra), and apomorphine (a dopamine receptor agonist approved for ED treatment in Europe as Uprima but not approved in the United States as a standalone ED product). All four are delivered together in a single sublingual liquid dose.
Three of those four are PDE5 inhibitors — they work by increasing blood flow. The fourth, apomorphine, works through your central nervous system by targeting dopamine pathways involved in sexual arousal and desire. The combination is designed for men whose ED involves more than just a blood flow problem — men who also experience reduced desire, performance anxiety, or inconsistent response to single-drug treatments.
Each individual ingredient has established FDA approval and extensive published research. The specific four-ingredient combination has not been studied as a finished compounded product through published clinical trials. This is how compounded medications work — they combine approved ingredients in new formulations without the combined product going through separate FDA review.
Who This Is Actually Designed For
QUAD is not a first-line treatment. If you have never tried ED medication before, a standard prescription for sildenafil or tadalafil from your doctor is the appropriate starting point. Those are well-studied, FDA-approved, widely available, and less expensive as generic options. The sublingual delivery format of QUAD is designed for men who have already tried those options and want something different.
QUAD is designed for men in a specific situation. You have tried single-ingredient ED medications and found them inconsistent or insufficient. You find the 30-to-60-minute onset window of traditional pills disruptive. You experience a desire or arousal deficit alongside the physical symptoms — meaning the medication works mechanically but you rarely feel interested. Or you want a broader response window without needing to time a pill around anticipated activity.
If that describes your situation, a multi-mechanism approach like QUAD may be worth discussing with a clinician. If you are satisfied with standard ED medication, there is no clinical reason to switch to a more complex formulation.
Safety Considerations You Cannot Skip
Combining multiple PDE5 inhibitors in a single formulation requires careful medical oversight. The most critical safety issue is the absolute contraindication with nitrate medications. If you take any form of nitroglycerin, isosorbide, or amyl nitrite, you cannot use QUAD or any PDE5 inhibitor. The combination causes severe drops in blood pressure that can be life-threatening.
You also need to disclose all blood pressure medications, alpha-blockers, and CYP3A4 inhibitors during the intake process. Multiple PDE5 agents together may produce additive effects on blood pressure that single-agent therapy does not.
Erectile dysfunction itself is often an early warning sign of cardiovascular disease — research suggests ED frequently appears two to five years before coronary artery disease is diagnosed. Getting evaluated for ED is not just about sexual function. It is an opportunity to catch cardiovascular problems early. Tell your doctor.
The Enrollment Process and What to Verify
QUAD is dispensed through MEDVi's telehealth platform. You complete a medical intake form, a licensed clinician reviews your health information, and if the prescription is approved, a compounding pharmacy prepares and ships the medication. Approval is not guaranteed — the clinician has full discretion to decline based on your health profile.
Before enrolling, verify the same things you would verify for any telehealth prescription program. Confirm the three-entity structure — the platform, the prescribing clinicians, and the compounding pharmacy are separate entities. Check the prescribing clinician's license through your state medical board. Review the billing terms, cancellation policy, and refund terms before you pay. For a practical walkthrough of telehealth enrollment protections, see our enrollment fine print guide — it applies to ED telehealth programs too, not just GLP-1.
For the complete picture of MEDVi's company-level situation — including the FDA warning letter, consumer review data, litigation status, and verified facts about the business — read our full MEDVi fact-check.
View the current MEDVi QUAD program (official MEDVi page)
Pricing and program details are subject to change. Verify current terms on the official MEDVi website before enrolling. Compounded medications are not FDA-approved as finished products. The individual ingredients in QUAD have established FDA approvals for specific indications. Results vary based on individual health factors. A prescription is not guaranteed.
This article is for informational purposes only. It is not medical advice. Erectile dysfunction should be evaluated by a qualified healthcare professional. Always consult your own doctor before starting any prescription ED medication.
MedicalFoundationOfNC.org Editorial Team | Published April 2026